Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

First Committee Meeting Summary - RiaSTAP

Date: August 8, 2008         Time: 2:30 PM

From: Vasantha Kumar

To: STN 125317/0

Re: First Committee Meeting for CSLB’s Human Fibrinogen Concentrate, RiaSTAP

FDA Participants:

Vasantha Kumar
Laura Wood
Nisha jain
Roman Drews
La’Nissa Brown
Boris Zaslavsky
Rebecca Olin
Loan Nguyen
Christine Drabick
Iftekhar Mahmood
Craig Zinderman
Tim Lee
Lisa Stockbridge
Faith Barash
Nannette Cagungun


Fibrinogen for intravenous use was marketed in the United States by several companies in the twentieth century. It was used to treat not only congenital fibrinogen deficiency, but also to treat obstetric (post-partum) bleeding. The FDA revoked all licenses for fibrinogen concentrates in 1977 because of the risk for hepatitis infection and a suspected lack of effectiveness in obstetric use. Several fibrin sealants are currently licensed in the U.S., but no fibrinogen for intravenous use is currently licensed. When licensed, RiaSTAP™ will have orphan drug status in the U.S. The B LA was submitted under the Accelerated Approval procedure.

Human fibrinogen concentrate, pasteurized (HFCP) is a concentrated form of human fibrinogen (coagulation factor I) derived from human plasma. The proposed indication for HFCP is for the treatment of patients with congenital fibrinogen deficiency, which comprises congenital afibrinogenemia, hypofibrinogenemia and dysfibrinogenemia. Determination of patients’ fibrinogen levels is recommended prior to and during treatment with HFCP, to maintain fibrinogen levels. The usual starting dose for adults is 1-2 grams, to obtain a replacement level or at or above .5-.8 g/L. Normal levels range from 200 – 450 mg/dl. If the fibrinogen level is unknown, the recommended dose is 70 mg/kg. HFCP is supplied as lyophilized powder and, after reconstitution, administered by slow, intravenous infusion. The labeled amount of HFCP is 1 g of fibrinogen with the actual potency for each lot indicated on the vial label and carton. The proposed trade name for HFCP is RiaSTAP.

Congenital fibrinogen deficiency is a very rare bleeding disorder. Hereditary afibrinogenemia affects an estimated 150-300 people in the US, based on published prevalence data. The prevalence of hypofibrinogenemia and dysfibrinogenemia are unknown. Patients with any of these conditions are treated for bleeding either by substitution with a cryoprecipitate or fresh frozen plasma. There are no fibrinogen concentrate products currently approved in the US.


The purpose and the outcome of this meeting are presented below:

  • To ensure the submission is complete.
    The submission was accepted to be complete.
  • To ensure a reviewer is assigned to review each section of the supplement.
    A reviewer from each discipline was assigned to review their respective sections and all the reviewers had received the modules for their respective disciplines
  • To identify if consult reviewers are needed in the review process.
    No consult reviewer seemed to be needed at this point
  • To identify follow up activities to be completed before the next meeting (Filing Meeting). The Filing Meeting is scheduled for 29-August-2008.
    Information requests from PK reviewer and APLB reviewer to be sent to the sponsor
  • To share the review findings to date and advice if there are any actions required at this time.
    Information requests for PK data and Pharmacovigilance plans were discussed. This submission had been granted an Orphan Drug designation and a fast Track designation was granted for a priority review based on serious life threatening condition (congenital afibrinogenemia) and unmet medical needs. The PLR team would review the package insert at the earliest. It was decided that this submission had to be discussed at the BPAC meeting scheduled for 9 Jan 2009. The review team was alerted that because of the new requirements under FDAAA and because there are Post Marketing Requirements, the approval letter and the labeling have to be submitted to the CBER and CDER Safety Working Groups by 16 December 2008.
  • To advise if others need to be included in this review.
    No other reviewer was found necessary at this point of time

 List of Reviewers:

ClinicalNisha JainModules 1 & 2, Module 5
CMCLaura Wood (Chair)
Ze Peng
Tim Lee
Full set
Additional CMCRoman DrewsModules 1 & 2, Module 3
Pharm/ToxLa'Nissa BrownModules 1 & 2, Module 4
BiostatisticianBoris ZaslavskyModules 1 & 2, Module 5
DMPQRebecca OlinFull set
APLBLoan Nguyen
Lisa Stockbridge
Modules 1 & 2
BIMOChris DrabickModules 1 & 2, Module 5
PKIftekhar MahmoodModules 1 & 2 , Module 5
OBECraig Zinderman
Faith Barash
Modules 1 & 2, Module 5
RPMVasantha KumarFull set (share with Iftekhar)
Archival Full set


Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 06/02/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English